Generic Victrelis Availability
VICTRELIS (boceprevir - capsule;oral)
Has a generic version of Victrelis been approved?
No. There is currently no therapeutically equivalent version of Victrelis available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Victrelis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pharmaceutical formulations and methods of treatment using the same
Issued: August 10, 2010
Inventor(s): Malcolm; Bruce A. & Bradley; Prudence K. & Pavlovsky; Anastasia & Cho; Wing-Kee Philip & Qiu; Zhihui
Assignee(s): Schering Corporation
Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.Patent expiration dates:
- November 11, 2027✓✓
- November 11, 2027
Administration of HCV protease inhibitors in combination with food to improve bioavailability
Issued: February 21, 2012
Inventor(s): Zhang; Jenny & Gupta; Samir K.
Assignee(s): Schering Corporation
Methods of treating, preventing or ameliorating one or more symptoms of hepatitis C in a subject comprising the step of administering at least one HCV protease inhibitor in combination with food are provided. Also provided are methods of increasing bioavailability of an HCV protease inhibitor and methods of increasing serum levels of an HCV protease inhibitor in a subject. All methods comprise adminstering at least one HCV protease inhibitor in combination with food, the at least one HCV protease inhibitor selected from the group consisting of compounds of Formulae I-XXVI, described herein. Administration of compounds of the present invention in combination with food provides improved bioavailability and increased peak serum levels of the compounds as compared to administration without food.Patent expiration dates:
- March 17, 2027✓
- March 17, 2027
Peptides as NS3-serine protease inhibitors of hepatitis C virus
Issued: April 3, 2012
Inventor(s): Saksena; Anil K. & Girijavallabhan; Viyyoor Moopil & Lovey; Raymond G. & Jao; Edwin & Bennett; Frank & McCormick; Jinping L. & Wang; Haiyan & Pike; Russell E. & Bogen; Stephane L. & Chan; Tin-Yau & Liu; Yi-Tsung & Zhu; Zhaoning & Njoroge; F. George & Arasappan; Ashok & Parekh; Tejal
Assignee(s): Schering Corporation Dendreon Corporation
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.Patent expiration dates:
- February 22, 2022✓✓✓
- February 22, 2022
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- February 13, 2016 -
- February 27, 2016 - UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
- May 13, 2016 -
- Victrelis Consumer Information (Drugs.com)
- Victrelis Consumer Information (Wolters Kluwer)
- Victrelis Consumer Information (Cerner Multum)
- Victrelis Advanced Consumer Information (Micromedex®)
- Victrelis AHFS DI Monographs (ASHP)
- Boceprevir Consumer Information (Wolters Kluwer)
- Boceprevir Consumer Information (Cerner Multum)
- Boceprevir Advanced Consumer Information (Micromedex®)
- Boceprevir AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|